Pappa Georgia, Sgouros Dimitrios, Theodoropoulos Konstantinos, Kanelleas Antonios, Bozi Evangelia, Gregoriou Stamatios, Krasagakis Konstantinos, Katoulis Alexander C
2nd Department of Dermatology and Venereology, "Attikon" General University Hospital, Medical School, National and Kapodistrian University of Athens, 12462 Athens, Greece.
1st Department of Dermatology and Venereology, "Andreas Suggros" Hospital, Medical School, National and Kapodistrian University of Athens, 16121 Athens, Greece.
J Clin Med. 2022 Sep 24;11(19):5633. doi: 10.3390/jcm11195633.
Atopic dermatitis (AD) is a common inflammatory skin disease with a complex pathophysiology, intertwining immune dysregulation, epidermal barrier dysfunction, IgE sensitization, environmental factors and genetic predisposition. It has been recently identified that interleukins -4 and -13 play crucial roles in the type-2-driven inflammation that characterizes AD, contributing to its symptomatology. Novel therapeutic approaches that target Th2 cytokines and their respective pathways have been developed, aiming to optimize the treatment of AD.
特应性皮炎（AD）是一种常见的炎症性皮肤病，其病理生理学复杂，涉及免疫失调、表皮屏障功能障碍、IgE致敏、环境因素和遗传易感性。最近发现，白细胞介素-4和-13在以2型为主导的炎症中起关键作用，这种炎症是AD的特征，导致其症状。针对Th2细胞因子及其各自途径的新型治疗方法已经开发出来，旨在优化AD的治疗。
